|
|||||
|
|
|
|
|
|
| |||||
 |
 |
||||||
|
 |
 |
 |
 |
 |
|
 |
|
CANTEST Biopharma Services appoints Director of BiopharmaceuticsBurnaby, BC. CANTEST is pleased to announce the appointment of Humphrey Tebit to head up its newly created Biopharmaceutics Department. Don Enns, President & CEO of CANTEST, explains: “The addition of Humphrey to our BioPharma Services team is well aligned with our growth strategy for this division and our commitment to be a fully integrated Life Sciences company. The breadth of expertise now available at CANTEST BioPharma Services allows us to offer a full suite of Phase I and Bioequivalence services, ranging from study design to clinical trials and bioanalytical testing, as well as statistics and data management.” In his new role, Mr. Tebit will be responsible for setting up an FDA and ICH compliant Biopharmaceutics department within CANTEST’s BioPharma Services group and work very closely with drug development companies on study design and regulatory submissions. Mr. Tebit brings to CANTEST over 10 years experience in creating and evaluating study designs for both non-clinical and clinical development programs. Most recently, he was employed at two of Canada’s largest drug manufacturers: Apotex Inc. and Genpharm Inc., a subsidiary of Merck Generics UK, both located in Toronto. Before coming to Canada, he worked in the UK, after graduating in 1994 from University of Reading with a Master’s degree in Biometry (Applied Statistics). Mr. Tebit has been responsible for the design and implementation of over 100 studies across North America and Europe. About CANTEST BioPharma Services About CANTEST Media contact: |
|
||||||||||
|
|
|
|||||||||||
|
|
|
|
|
|
||||||||
 |
 |
 |
 |
 |
 |